Usage, dosage and precautions of Ixabepilone

Ixabepilone is an intravenous anti-tumor drug commonly used to treat patients with anthracycline- and taxane-resistant advanced or metastatic breast cancer. The recommended dose is 40 mg/m² based on body surface area once every three weeks, with an intravenous infusion time of approximately 3 hours. For patients whose body surface area exceeds 2.2 m², 2.2 m² should be used as the upper limit for calculation to avoid excessive doses leading to enhanced toxic reactions. Antiallergic treatment, such as antihistamines or corticosteroids, is often given before administration to reduce the risk of allergy.

Dose adjustment is critical when using ixabepilone. If the patient develops severe myelosuppression (such as neutropenia) or peripheral neuropathy, administration should be suspended and treatment should be continued at a reduced dose after recovery. Patients with abnormal liver function should also use it with caution because the drug is mainly metabolized by the liver and is contraindicated in patients with severe liver damage. For patients with mild to moderate hepatic impairment, doctors usually reduce the dose appropriately and closely monitor ALT, AST, and bilirubin levels.

During the medication process, the choice of infusion route and control of the administration speed are equally important. Ixabepilone needs to be infused through a central venous access to avoid local irritation or phlebitis. The medicinal solution should be used immediately after preparation and avoid mixing with other medications. During the entire treatment cycle, it is recommended to conduct regular hematology tests, especially to confirm the neutrophil and platelet counts before each cycle to ensure that the patient has sufficient bone marrow reserve capacity.

In terms of precautions, ixabepilone may cause adverse reactions to the nervous system, including numbness, tingling, and movement disorders. If neurological symptoms continue to worsen, you should communicate with your doctor immediately to evaluate the need to discontinue or reduce the dose. In addition, female patients should avoid pregnancy during treatment because animal experiments have shown that the drug may have toxic effects on embryonic development. It is also not recommended for breastfeeding women.

Reference materials:https://www.drugs.com/mtm/ixabepilone.html